CC
AGRX

Caxton Corporation’s Agile Therapeutics AGRX Stock Holding History

Caxton Corporation’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-907
Closed -$4.66M – 30
2018
Q1 		$4.66M Sell
907
-3
-0.3% -$19.8K 5.06% 6
2017
Q4 		$4.9M Hold
910
– – 5.95% 5
2017
Q3 		$8.12M Buy
910
+98
+12% +$753K 8.26% 4
2017
Q2 		$6.09M Hold
812
– – 9.5% 3
2017
Q1 		$5.2M Sell
812
-250
-24% -$1.26M 14.85% 2
2016
Q4 		$12.1M Buy
1,062
+175
+20% +$2.45M 41.3% 2
2016
Q3 		$12.4M Buy
887
+97
+12% +$1.38M 55.46% 1
2016
Q2 		$12M Buy
790
+76
+11% +$1.04M 13.57% 2
2016
Q1 		$8.87M Buy
714
+702
+5,850% +$9.06M 12.24% 3
2015
Q4 		$225K Hold
12
– – 0.94% 10
2015
Q3 		$155K Buy
12
+3
+33% +$53.3K 0.21% 16
2015
Q2 		$151K Sell
9
-4
-31% -$85.4K 0.16% 16
2015
Q1 		$248K Sell
13
-2
-13% -$35.1K 0.3% 14
2014
Q4 		$182K Buy
15
+1
+7% +$12.7K 0.21% 6
2014
Q3 		$200K Buy
14
+2
+17% +$30.9K 0.21% 4
2014
Q2 		$217K Buy
+12
New +$174K 0.17% 4

Other funds holding AGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caxton Corporation's AGRX Position: Q2 2018 in Review

Caxton Corporation sold out of Agile Therapeutics (AGRX) in Q2 2018, closing a stake of 907 shares — an estimated $4.66M sold.

Caxton Corporation first reported a position in AGRX in Q2 2014 and held it in 16 quarters. The position peaked at $12.4M in Q3 2016. 38 funds tracked by Wall St. Rank hold AGRX as of Q2 2018.

  • Caxton Corporation reported no remaining Agile Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Caxton Corporation sold 907 Agile Therapeutics shares in Q2 2018, an estimated $4.66M.
  • Caxton Corporation first reported a position in Agile Therapeutics in Q2 2014 and held it in 16 quarters.
  • Caxton Corporation's Agile Therapeutics position peaked at $12.4M in Q3 2016.
  • 38 funds tracked by Wall St. Rank held Agile Therapeutics as of Q2 2018.

Based on Caxton Corporation's 13F filing for Q2 2018, filed 14 Aug 2018.